SCHEMBL551203

SCHEMBL551203

C=CC(=C)[Si](OCC)(OCC)OCC

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2503776 0.81 HPGD (0.33) TSHR
SCHEMBL10348462 0.78 ALDH1A1 (0.33) ALDH1A1TSHR
SCHEMBL2507515 0.78 TSHR (0.44) ALDH1A1TSHR
SCHEMBL2843011 0.73 ALDH1A1 (0.39) ALDH1A1TP53TSHR
SCHEMBL22721289 0.73
SCHEMBL137982 0.73
SCHEMBL25183119 0.72
SCHEMBL962616 0.70
SCHEMBL28264054 0.70
SCHEMBL2496519 0.70 ALDH1A1 (0.35) ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188615-A1 Gapfill Methods and Processing Assemblies ASM IP HOLDING B.V. (NL) 2025-06-12 US disclosed
US-12252790-B2 Gapfill methods and processing assemblies ASM IP HOLDING B.V. (NL) 2025-03-18 US disclosed
US-20240117494-A1 Gapfill methods and processing assemblies ASM IP HOLDING B.V. (NL) 2024-04-11 US disclosed
CN-110408282-A Coating for preventing blockage of low-temperature heat exchange equipment of ultra-low emission unit and preparation method thereof HUANENG POWER INT INC 2019-11-05 CN disclosed
US-8110695-B2 Compounds and compositions containing silicon and/or other heteroatoms and/or metals and methods of making and using them WELKER MARK E (US) 2012-02-07 US disclosed
US-8110695-B2 Compounds and compositions containing silicon and/or other heteroatoms and/or metals and methods of making and using them WELKER MARK E (US) 2012-02-07 US disclosed
US-20110245398-A1 METHOD FOR PRODUCING CONJUGATED DIENE POLYMER COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-06 US disclosed
US-20100056801-A1 Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them WELKER MARK E 2010-03-04 US disclosed
US-20100056801-A1 Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them WELKER MARK E 2010-03-04 US disclosed
WO-2008054718-A2 COMPOUNDS AND COMPOSITIONS CONTAINING SILICON AND/OR OTHER HETEROATOMS AND/OR METALS AND METHODS OF MAKING AND USING THEM WAKE FOREST UNIVERSITY (US) 2008-05-08 WO disclosed
EP-0189174-B1 POLYMERS OF SUBSTITUTED 1,3-BUTADIENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1990-04-25 EP disclosed
US-4730031-A Polymers of substituted 1,3-butadiene compounds having reactive silyl groups and process for their preparation NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1988-03-08 US disclosed
EP-0189174-A1 Polymers of substituted 1,3-butadiene compounds and process for their preparation NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056801-A1 Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them CA6, SOD1, CA1 ALDH1A1 2774/4885TP53 158/4885TSHR 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.